Zhitong Finance App News, Haixi New Pharmaceutical (02637.HK) issued an announcement. The Chinese phase I clinical study of HX9428 to treat neovascular age-related macular degeneration (“NaMD”) has completed 24 weeks of treatment data observation; China's phase II dose extension study is still ongoing, and phased clinical data have been obtained.

Zhitongcaijing · 2d ago
Zhitong Finance App News, Haixi New Pharmaceutical (02637.HK) issued an announcement. The Chinese phase I clinical study of HX9428 to treat neovascular age-related macular degeneration (“NaMD”) has completed 24 weeks of treatment data observation; China's phase II dose extension study is still ongoing, and phased clinical data have been obtained.